Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Feb 1;34(1).
doi: 10.1515/dmpt-2018-0032.

Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles

Mehran Alavi  1 , Mehrdad Hamidi  2   3
Affiliations
Review

Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles

Mehran Alavi et al. Drug Metab Pers Ther. .

Abstract

Considerable development in the application of injectable drug delivery systems for cancer therapy has occurred in the last few decades. These improvements include liposomes, lipid nanoparticles (LNPs), and other nanoparticles with or without macromolecular conjugates. For example, liposomal doxorubicin modified by poly(ethylene glycol) (Doxil) was the first liposome with anti-cancer effects which was approved by the US Food and Drug Administration, whereas Abraxane (modified albumin nanoparticles loaded by paclitaxel) was recently confirmed for the treatment of breast cancer. Recently, drug delivery systems by LNPs are an emerging technology with numerous advantages over conventional liposomes and chemotherapy using free drug treatment of cancer. These properties are biocompatibility, controlled and sustained release of anti-tumor drugs, and lower toxicity. Valuable experiments on these drug delivery systems offer better treatment of multidrug-resistant cancers and lower cardiotoxicity. LNPs have been presented with high functionality in chemotherapeutic targeting of breast and prostate cancer. The basis for this targeting behavior has been shown to be both passive and active targeting. The main objective of this review was an overview of the current position of the liposome-based drug delivery systems in targeted anticancer chemotherapy.

Keywords: active targeting; cancer therapy; lipid nanoparticles; liposomes; passive targeting.

PubMed Disclaimer

References

    1. Gabizon AA. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 2001;19:424–36.
    1. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23:7794–803.
    1. Fu S, Culotta KS, Falchook GS, Hong DS, Myers AL, Zhang YP, et al. Erratum to: Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases. Cancer Chemother Pharmacol 2016;77:881.
    1. Jain MM, Gupte SU, Patil SG, Pathak AB, Deshmukh CD, Bhatt N, et al. Paclitaxel injection concentrate for nanodispersion versus nab-paclitaxel in women with metastatic breast cancer: a multicenter, randomized, comparative phase II/III study. Breast Cancer Res Treat 2016;156:125–34.
    1. Kapp M, Kosmala A, Kircher S, Luber V, Kunzmann V. Exceptional response to nanoparticle albumin-bound paclitaxel and gemcitabine in a patient with a refractory adenocarcinoma of the ampulla of Vater. Case Rep Oncol 2016;9:15–24.

MeSH terms

LinkOut - more resources